Optimal Biopsy Location for Assessments in Crohn's Disease
Determining the optimal location for biopsy procurement in Crohn's disease may lead to a more accurate assessment of disease activity. Alimentary Pharmacology & Therapeutics
View ArticleSilicon Therapeutics Expands Board by Naming Roger J. Pomerantz MD FACP as...
Silicon Therapeutics announced today that it has named Roger J. Pomerantz MD FACP a current member of the Board of Directors to Chairman and appointed Mark J. Gilbert MD to the Board of Directors."We...
View ArticleHuman medicines European public assessment report EPAR Remicade infliximab...
Human medicines European public assessment report EPAR Remicade infliximab Spondylitis AnkylosingArthritis RheumatoidPsoriasisCrohn DiseaseArthritis PsoriaticColitis Ulcerative Date of authorisation...
View ArticleHuman medicines European public assessment report EPAR Humira adalimumab...
Human medicines European public assessment report EPAR Humira adalimumab Spondylitis AnkylosingArthritis Juvenile RheumatoidUveitisColitis UlcerativePsoriasisArthritis PsoriaticCrohn DiseaseArthritis...
View ArticleEtanercept Tx for Autoimmune Disease May Up Risk for IBD
MONDAY July 15 2019 Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease CD or ulcerative colitis UC while under treatment with etanercept according to a...
View ArticleRho Associated Protein Kinase 1 Renal Carcinoma Antigen NY REN 35 or Rho...
Rho Associated Protein Kinase 1 Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1 Pipeline Review H1 2019SummaryRho...
View ArticleDevice Week 19 July 2019 All About Earnings Johnson & Johnson&39;s...
In this edition of Device Week Medtech Insight&39;s managing editor Marion Webb chats with deputy editor Reed Miller about recent...&160;&160;&160;&160;
View ArticleSubcutaneous Formulation of Takedas Entyvio Hits the Mark in Crohns Trial
Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.
View ArticleInvestigational Subcutaneous Formulation of Vedolizumab Meets Primary...
Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency EMA and U.S. Food and Drug Administration FDATakeda Pharmaceutical Company...
View ArticleFDA Says No To BHVN Detraxi Eyeing Solution For Blood Shortage MRKR On Watch
Today's Daily Dose brings you news about the FDA decisions related to Biohaven's NURTEC and Celgene's OTEZLA; interim data from Marker's MultiTAA T cell therapy trial and Takeda's phase III trial...
View ArticleTakeda's subcutaneous formulation of Entyvio hits main goal in latestage...
Takeda's subcutaneous formulation of Entyvio hits main goal in latestage Crohn's disease trial httpswww.firstwordpharma.comnode1654130
View ArticleRedHill Biopharma Reports Second Quarter 2019 Financial Results and...
Key Highlights and Upcoming Milestones U.S. FDA acceptance of the New Drug Application NDA for Talicia for H. pylori for priority review and assignment of a target PDUFA action date of November 2...
View ArticleTakeda's subcutaneous formulation of Entyvio smashes primary endpoint in...
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gutselective biologic Entyvio vedolizumab showing that the therapy met its primary endpoint as a maintenance treatment for...
View ArticleTakeda's subcutaneous formulation of Entyvio smashes primary endpoint in...
Takeda's subcutaneous formulation of Entyvio smashes primary endpoint in Crohn's disease httpbit.ly2y6eExe pharma pic.twitter.comvHGIuxQt1t
View ArticleTakedas Investigational Subcutaneous Formulation of Vedolizumab Meets Primary...
OSAKA Japan&8211;BUSINESS WIRE&8211;Takeda Pharmaceutical Company Limited TSE4502NYSETAK Takeda today announced topline results from the VISIBLE 2 clinical trial evaluating the efficacy and...
View ArticleFDA Approves Samsung Bioepis' HADLIMA adalimumabbwwd
Samsung Bioepis secures third FDA approval in the past seven monthsSamsung Bioepis becomes the first company to receive FDA approvals for biosimilars referencing all three firstgeneration antiTNF...
View ArticleHumira biosimilar from Samsung Bioepis and MSD wins marketing authorisation...
Its another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVies Humira the worlds bestselling medicine has received marketing authorisation from the FDA.The approval...
View ArticleHow do interactions between gut bacteria and fungi exacerbate crohn's disease
Case Western Reserve University Case Western Reserve School of Medicine and University Hospitals Cleveland Medical Center Researcher receives NIH funding to investigate how Interactions between gut...
View ArticleFDA Approves Samsung Bioepis Hadlima a Biosimilar Referencing Humira
INCHEON Korea&8211;BUSINESS WIRE&8211;Samsung Bioepis Co. Ltd. today announced that the US Food and Drug Administration FDA has approved HADLIMA adalimumabbwwd a biosimilar referencing HUMIRAÂ...
View Article